secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K/A
Filed at:   2022-06-01T23:59:59+00:00
Accession:  0001193125-22-165220
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna CFO David Meline to retire by Dec 31, 2022; will serve as consultant through Mar 2026
--------------------------------------------------------------------------------

- David Meline continues as CFO until Dec 31, 2022 (or earlier if successor starts); consulting services to Mar 2, 2026.
- Continued vesting in new hire equity award (to July 8, 2024), 2021 annual grant (to July 8, 2024), and 2022 annual grant (to Mar 2, 2026).
- Prorated 2022 annual bonus at target; vested stock options extend 12 months after consulting period (not beyond original expiration).
- Agreement supersedes April 10, 2022 retirement deal; includes non-disparagement, cooperation, and general release of claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000119312522165220/0001193125-22-165220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000119312522165220/d364287d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-165220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer